# Quality Review: Doxorubicin-NF1 Toxicity v2

## Summary Verdict

**PASS** | Templates: Safety/Off-Target (T7) + Drug Discovery (T1) combined | Median evidence score: 0.83 (L3 Functional)

**Top 3 Strengths**:
1. Full LOCATE-RETRIEVE cycle for all 11 gene nodes with 5 required fields validated
2. All 8 NCT IDs verified via clinicaltrials_get_trial with detailed protocol data
3. Negative search results documented (NF1 cardiotoxicity trials, ChEMBL activity endpoint)

**Top 3 Issues**:
1. Synapse grounding not performed (0% coverage)
2. ChEMBL activity endpoint (IC50/Ki) not available in MCP toolkit
3. No doxorubicin + MEK inhibitor combination trial data

## Dimension Scores

| # | Dimension | Score (0-10) | Status | Notes |
|---|-----------|-------------|--------|-------|
| 1 | CURIE Resolution | 10 | PASS | All 11 genes, 4 drugs, 3 diseases use proper CURIEs |
| 2 | Source Attribution | 9 | PASS | >95% of claims cite [Source: tool(param)]; negative results documented |
| 3 | LOCATE-RETRIEVE | 10 | PASS | Two-step pattern for all entities: search -> get for HGNC, ChEMBL, PubChem, UniProt |
| 4 | Disease CURIE | 9 | PASS | MONDO_0018975 (NF1), EFO_0000318 (cardiomyopathy), EFO_0000760 (MPNST) present |
| 5 | OT Pagination | 8 | PASS | opentargets_get_associations called with page_size=10; pagination available |
| 6 | Evidence Grading | 9 | PASS | 10 claims individually graded with base levels + modifiers; overall median computed |
| 7 | LOF Filter | 10 | PASS | NF1 LOF explicitly analyzed; only downstream inhibitors (MEK inhibitors) recommended |
| 8 | Trial Validation | 10 | PASS | All 8 NCT IDs verified via clinicaltrials_get_trial with full protocol data |
| 9 | Completeness | 8 | PASS | CQ answered with 3 complementary strategies; ChEMBL activity gap documented |
| 10 | Hallucination Risk | LOW | PASS | All entities traceable to MCP tool outputs; no synthetic CURIEs or NCT IDs |

## Detailed Findings

### 1. CURIE Resolution (10/10)
- 11 gene nodes: HGNC:7765, HGNC:11989, HGNC:11990, HGNC:6407, HGNC:1097, HGNC:11998, HGNC:270, HGNC:17768, HGNC:20249, HGNC:6840, HGNC:6842
- 4 drug nodes: CHEMBL:53463, CHEMBL:1614701, CHEMBL:2103875, CHEMBL:1738
- 3 disease nodes: MONDO_0018975, EFO_0000318, EFO_0000760
- Cross-database IDs: Ensembl, UniProt, Entrez, PubChem all present where available
- All CURIEs in proper format (namespace:identifier)

### 2. Source Attribution (9/10)
- Factual claims cite specific tool calls: `[Source: hgnc_get_gene(HGNC:7765)]`
- STRING interaction scores attributed: `[Source: string_get_interactions(STRING:9606.ENSP00000351015)]`
- Negative results documented with tool name: `[No data: clinicaltrials_search_trials(...) returned 0]`
- Minor: Some pathway membership claims reference WikiPathways search rather than get_pathway_components

### 3. LOCATE-RETRIEVE (10/10)
All entity types follow two-step pattern:
- Genes: `hgnc_search_genes` -> `hgnc_get_gene`
- Drugs: `chembl_search_compounds` -> `chembl_get_compound`; also `pubchem_search_compounds` -> `pubchem_get_compound` for doxorubicin
- Proteins: `uniprot_search_proteins` -> `uniprot_get_protein`
- Diseases: Via `opentargets_get_associations` (disease CURIEs extracted from association results)
- Trials: `clinicaltrials_search_trials` -> `clinicaltrials_get_trial`
- Pathways: `wikipathways_get_pathways_for_gene` -> `wikipathways_get_pathway`

### 4. Disease CURIE (9/10)
- NF1 disease: MONDO_0018975 (score 0.885 from OT)
- Cardiomyopathy: EFO_0000318 (score 0.465 from OT)
- MPNST: EFO_0000760 (score 0.692 from OT)
- All sourced from opentargets_get_associations

### 5. OT Pagination (8/10)
- opentargets_get_associations called for NF1 (ENSG00000196712), TOP2A (ENSG00000131747), TOP2B (ENSG00000077097) with page_size=10
- Pagination cursors returned for all queries (total_count: 1680, 650, 306 respectively)
- Only first page retrieved; subsequent pages not explored (acceptable for this query)

### 6. Evidence Grading (9/10)
- 10 claims individually graded with numeric scores
- Base levels correctly assigned (L1-L4)
- Modifiers applied: active trial (+0.10), mechanism match (+0.10), literature (+0.05), high STRING (+0.05), single source (-0.10)
- Overall median: 0.83 (L3)
- Range: 0.30 - 1.00
- No claims below L1 threshold

### 7. LOF Filter (10/10)
- NF1 explicitly identified as loss-of-function tumor suppressor
- Consequence analyzed: "Loss of NF1 GAP activity leads to constitutive RAS-GTP accumulation"
- Therapeutic implication: "Only inhibitors acting DOWNSTREAM of NF1 in the RAS pathway are appropriate"
- No agonists recommended for the LOF context
- Mechanism mismatch modifier not needed (all recommended drugs are inhibitors)

### 8. Trial Validation (10/10)
- 8 NCT IDs searched via clinicaltrials_search_trials
- All 8 verified via clinicaltrials_get_trial with full protocol data
- Verification results: 8/8 VALIDATED, 0 INVALID
- Trial statuses accurately reported (COMPLETED, ACTIVE_NOT_RECRUITING, NOT_YET_RECRUITING, TERMINATED)
- NF1-specific cardiotoxicity trials: 0 found (documented)

### 9. Completeness (8/10)
- CQ fully answered with three complementary strategies
- Gene nodes: 11 with all 5 required fields
- Drug candidates: 3 with mechanisms and evidence levels
- Clinical trials: 8 verified
- Gaps: ChEMBL activity data, Synapse grounding, combination trial data

### 10. Hallucination Risk (LOW)
- All gene symbols match HGNC records
- All drug names match ChEMBL records
- All NCT IDs verified against ClinicalTrials.gov
- No synthetic CURIEs detected
- Function text paraphrases UniProt with attribution
- Negative results reported rather than filled from training knowledge

## Failure Classification

| Finding | Classification | Impact |
|---------|---------------|--------|
| Synapse grounding not performed | Presentation failure | PARTIAL — protocol step available but not executed |
| ChEMBL activity endpoint unavailable | External limitation | N/A — documented; not a protocol failure |
| No combination trial data | Data gap | N/A — documented in Gaps and Limitations |

## Overall Assessment

| Dimension | Score |
|-----------|-------|
| Protocol Execution | 9/10 |
| Presentation Quality | 8/10 |
| KG Structure | 9/10 |
| Synapse Grounding | 2/10 |
| **Overall** | **PASS** |

### Notes
- Protocol execution is strong with full LOCATE-RETRIEVE cycles and systematic phase progression
- KG JSON validates with 11 gene nodes (all with 5 required fields), 4 drugs, 3 diseases, 3 pathways, 8 trials
- Report follows combined T7+T1 template structure appropriately
- Synapse grounding is the primary gap; recommended for follow-up execution
- The LOF filter analysis is a standout feature, correctly identifying that only downstream pathway inhibitors are appropriate for NF1
